A: Only a confirmatory procedure such as biopsy and laboratory evaluation by a pathologist may be used to diagnose NPC. NP Screen™ is used in conjunction with other methods such as endoscopy, to increase the chance of accurate and early NPC detection, especially for early and obscured cancer.
A: NP Screen™ can only detect and assess a patient’s current risk of a developed NPC and can not predict future abnormalities.
A: NPC can only be cured by one of, or a combination of, radiation therapy, chemotherapy or surgery.
A: How rapidly NPC develops is not completely understood. Doctors experienced with NPC believe it can take six to twelve months (or even longer) for newly formed abnormalities to appear and become a clinically apparent cancer.
A: Similar to tests for cervical cancer, breast cancer and prostrate cancer, NP Screen™ should be taken regularly and can be done on a yearly basis if you are from a high risk population and risk, and have suspicious signs and symptoms of NPC. The test should be done in conjunction with other clinical detection methods, such as endoscopy so that the chance of detecting the cancer early can be improved significantly. In patients with a predisposition (i.e. genetic or family background) for NPC, semi-annual testing may be considered when monitoring endoscopy is being performed. Early detection lead to much better treatment outcome and survival.
A: NP Screen™ is Laboratory Developed Test (LDT) approved under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”). This test is now being reviewed by FDA and is approval pending. Consult with your physician on more details about FDA approval and regulations for NP Screen™.